

Dr. Charles Reay Mackay To Join Pfizer as Chief Scientific Officer, Inflammation and Immunology Research Unit

Monday, March 30, 2015 - 07:06am

NEW YORK--Pfizer Inc. announced today that Charles Reay Mackay, Ph.D., will join the company as Chief Scientific Officer for Pfizer's Inflammation and Immunology Research Unit. Professor Mackay will report directly to José-Carlos Gutiérrez-Ramos, Ph.D., group vice president of BioTherapeutics Research & Development, and will be based in Pfizer's R&D hub in Cambridge, MA.

"Professor Mackay's research has focused on understanding the fundamental mechanisms that regulate the immune system, developing new monoclonal antibody treatments for inflammation and exploring strategies to prevent inflammatory diseases through gut microbe/epithelial barrier modulation," said Dr. Gutiérrez-Ramos. "Professor Mackay brings to Pfizer a unique combination of scientific expertise, academic credentials and entrepreneurial spirit. His deep commitment to drug discovery and his unique skill set will help advance Pfizer's position as a global leader in inflammation and a collaborator of choice within the Cambridge community and beyond."

Professor Mackay will join Pfizer from Monash University in Australia, where he is a research fellow, and the Charles Perkins Center within the Faculty of Medicine at Sydney University, where he was Chair of Diabetes. Professor Mackay has also held important biotech leadership positions at LeukoSite Inc. and Millennium Therapeutics in Cambridge, Massachusetts. He has authored more than 160 peer-reviewed scientific publications and is a member of the Australian Academy of Science and was an Australia Fellow at the National Health and Medical Research Council of Australia.

"I am privileged to be joining a world-class team of scientists that has made an important contribution to the field of Inflammation and Immunology research," said Professor Mackay. "We have an important opportunity to advance a robust pipeline of novel agents that target the root cause of inflammation at a molecular level across several disease areas such as inflammatory bowel disease (IBD), lupus, psoriasis, Chronic Obstructive Pulmonary Disorder and other chronic diseases. We will also pursue other novel approaches that could help transform the way inflammatory diseases are treated."

Inflammation and Immunology is one of Pfizer's key therapeutic areas, where Pfizer has a unique opportunity to bring important potential new therapies to patients in need. As of February 2015, the Inflammation and Immunology pipeline includes 19 programs from Phase 1 through Registration.

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and

emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.

DISCLOSURE NOTICE: *The information contained in this release is as of March 30, 2015. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.*

This release contains forward-looking information about a Pfizer's pipeline of inflammation and immunology agents that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including, without limitation, the ability to meet anticipated clinical trial commencement and completion dates as well as the possibility of unfavorable clinical trial results, including unfavorable new clinical data and additional analyses of existing clinical data; whether and when new drug applications may be filed in any jurisdictions for any of these pipeline products; whether and when such applications may be approved by regulatory authorities, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of any of these pipeline products; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the SEC and available at www.sec.gov and www.pfizer.com.

Pfizer Inc. Dean Mastrojohn, 212-733-6944